United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genus pharmaceuticals ltd - brimonidine tartrate - eye drops - 2mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

genus pharmaceuticals limited - apomorphine hydrochloride - solution for injection - 10 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

genus pharmaceuticals limited - apomorphine hydrochloride - solution for infusion - 5 mg/ml

Malta - English - Medicines Authority

genus pharmaceuticals limited linthwaite, huddersfied hd7 5qh, united kingdom - mucopolysaccharide polysulfuric, acid ester, lauromacrogol - rectal ointment - mucopolysaccharide polysulfuric acid ester 0.2 % (w/w) lauromacrogol 400 5 % (w/w) - vasoprotectives

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine 50 mg in 1 g - lidocaine ointment 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. it is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidocaine ointment 5%.

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals llc - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduce serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: 1.      the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2.      the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. 3.      the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in m

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals llc - cyproheptadine hydrochloride (unii: nj82j0f8qc) (cyproheptadine - unii:2yhb6175do) - cyproheptadine hydrochloride 4 mg - perennial and seasonal allergic rhinitis vasomotor rhinitis allergic conjunctivitis due to inhalant allergens and foods mild, uncomplicated allergic skin manifestations of urticaria and angioedema. amelioration of allergic reactions to blood or plasma cold urticaria dermatographism as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. this drug should not be used in newborn or premature infants. because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. hypersensitivity to cyproheptadine and other drugs of similar chemical structure. monoamine oxidase inhibitor therapy (see drug interactions .) angle-closure glaucoma stenosing peptic ulcer symptomatic prostatic hypertrophy bladder neck obstruction pyloroduodenal obstruction elderly, debilitated patients

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - acetazolamide (unii: o3fx965v0i) (acetazolamide - unii:o3fx965v0i) - for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. acetazolamide is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent. hypersensitivity to acetazolamide or any excipients in the formulation. since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. long-term administration of acetazolamide is contraindicated in patients with chronic non-con

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - nadolol (unii: fen504330v) (nadolol - unii:fen504330v) - nadolol tablets are indicated for the long-term management of patients with angina pectoris. nadolol tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with nadolol tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure educati

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. pregnancy: probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animals under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.